#21 ·
MEDICAL REPORT
12/04/2013
The patient is presenting this case to the GI tumor protocol team. Diagnosis: Primary liver neoplasm.
Procedure: Biopsy performed on 10/31/2013 at Mount Sinai Medical Center.
Pathology report: Poorly differentiated hepatocellular carcinoma with
microangiovascular invasion.
Disease stage: c T3b N0 M0
Summary of diagnostic workup:
- Abdominal and pelvic MSCT (11/27/2013): A neoplastic process measuring 11x8x6.5 cm is visible in the right hepatic lobe (previously measured at 14.3x12.7x7.8 cm on the 10/18/2013 MSCT). There is thrombosis present in the portal vein, splenic vein, and superior mesenteric vein.
- Thoracic MSCT, brain imaging, and lumbar spine MRI: No evidence of metastatic spread.
- Lab results: GGT 206, AST 68, ALT 44, LDH 428.
- Tumor markers: AFP = 10.19, CA 19-9 = 43.96, CA 15-3 = 46.7, CA 125 = 35.1, NSE 25.3; CEA and CYFRA 21-1 are within normal limits.
Child-Pugh status: A (bilirubin 23, albumin 33, PV-INR 1.1, no ascites, no encephalopathy).
General condition is good. ECOG 1. No weight loss noted. Physical exam: negative for tumors. In October 2013, she was diagnosed with sensorimotor polyneuropathy of the lower extremities.
Team Decision:
Local therapy will be coordinated with the interventional radiologist alongside a prescription for systemic Sorafenib therapy. A Sorafenib approval request will be submitted to the drug approval committee. Once the medication is approved, the patient will be notified via telephone.
Upon the arrival of the medication to begin treatment, please present with current CBC, CMP, biochemistry (glucose, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, LDH, electrolytes) and the outpatient treatment referral, Dr. Smith.
12/04/2013
The patient is presenting this case to the GI tumor protocol team. Diagnosis: Primary liver neoplasm.
Procedure: Biopsy performed on 10/31/2013 at Mount Sinai Medical Center.
Pathology report: Poorly differentiated hepatocellular carcinoma with
microangiovascular invasion.
Disease stage: c T3b N0 M0
Summary of diagnostic workup:
- Abdominal and pelvic MSCT (11/27/2013): A neoplastic process measuring 11x8x6.5 cm is visible in the right hepatic lobe (previously measured at 14.3x12.7x7.8 cm on the 10/18/2013 MSCT). There is thrombosis present in the portal vein, splenic vein, and superior mesenteric vein.
- Thoracic MSCT, brain imaging, and lumbar spine MRI: No evidence of metastatic spread.
- Lab results: GGT 206, AST 68, ALT 44, LDH 428.
- Tumor markers: AFP = 10.19, CA 19-9 = 43.96, CA 15-3 = 46.7, CA 125 = 35.1, NSE 25.3; CEA and CYFRA 21-1 are within normal limits.
Child-Pugh status: A (bilirubin 23, albumin 33, PV-INR 1.1, no ascites, no encephalopathy).
General condition is good. ECOG 1. No weight loss noted. Physical exam: negative for tumors. In October 2013, she was diagnosed with sensorimotor polyneuropathy of the lower extremities.
Team Decision:
Local therapy will be coordinated with the interventional radiologist alongside a prescription for systemic Sorafenib therapy. A Sorafenib approval request will be submitted to the drug approval committee. Once the medication is approved, the patient will be notified via telephone.
Upon the arrival of the medication to begin treatment, please present with current CBC, CMP, biochemistry (glucose, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, LDH, electrolytes) and the outpatient treatment referral, Dr. Smith.